Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Morgan Stanley Maintains Equal-Weight on Esperion Therapeutics, Lowers Price Target to $17
Morgan Stanley analyst Jeffrey Hung maintains Esperion Therapeutics (NASDAQ:ESPR) with a Equal-Weight and lowers the price target from $22 to $17.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Needham Maintains Strong Buy on Esperion Therapeutics, Lowers Price Target to $114
Needham analyst Chad Messer maintains Esperion Therapeutics (NASDAQ:ESPR) with a Strong Buy and lowers the price target from $134 to $114.
